News & Press https://www.cttcanada.org/news/default.asp Tue, 23 Jun 2026 07:14:15 GMT Wed, 1 Apr 2026 16:17:00 GMT Copyright © 2026 CTTC CTTC Board of Directors Announcement https://www.cttcanada.org/news/news.asp?id=724664 https://www.cttcanada.org/news/news.asp?id=724664

CTTC would like to welcome the new CTTC President-Elect for 2026-2028, Dr. Dennis Kim!


 Dr. Dennis Kim is a Professor of Medicine at the Princess Margaret Cancer Centre at the University of Toronto where he is head of the Malignant Hematology Program. He has published 280 peer-reviewed papers. His 3 major subjects of research are: genomic-based biomarker development in post-transplant relapse and leukemia for measureable residual disease (MRD) monitoring, genomics in leukemias including chronic myeloid leukemia, and clinical development of graft-versus-host disease (GVHD) prevention/treatment. 

Dr. Kim is committed to fostering open communication and the sharing of best practices among the members and stakeholders within our organization, facilitating a collaborative research environment that encourages interdisciplinary cooperation, and driving forward the field of transplantation and cell therapy in Canada and beyond.

____________________________________________________________________________________________

CTTC would like to welcome the new CTTC Treasurer for 2026 - 2029, Dr. Christopher Lemieux

   
Dr. Christopher Lemieux is a Hematologist at the CHU de Québec-Université Laval. He received the Detweiler scholarship from the Royal College of Physicians and Surgeons of Canada, and the Stephen Couban price of the Canadian Hematology Society. He is currently director of the CAR-T program at the CHU de Québec-Université Laval and is a member of the immunocellular therapy network in Québec. He is a Clinical Associate Professor of Medicine and director of the Hematology fellowship program at Université Laval.

 
As Treasurer, Dr. Lemieux will ensure that CTTC's resources are well managed, its priorities well funded, and its mission sustainably supported. He is excited to take a more active leadership role in supporting CTTC's mission and to advance the strategic direction of the Society as a member of the CTTC Board of Directors.

____________________________________________________________________________________________
 
CTTC would like to welcome the new CTTC Education Director-At-Large for 2026 - 2029, Dr. Kareem Jamani. It was a close race, and we thank Drs. Mahmoud Elsawy, Craig Speziali, and Sita Bhella for running in this election.

   
Dr. Jamani is the Director of the Alberta Blood & Marrow Transplant Program adult long-term follow-up/survivorship clinic. His clinical practice involves leukemia and hematopoietic cell transplant (HCT)/cellular therapy, particularly for non-malignant diseases like hemoglobinopathies and autoimmune diseases. Dr. Jamani has held leadership positions in medical education at the University of Calgary, and is passionate about creating educational materials and experiences for trainees, multi-disciplinary teams, and patients and families. 
 As Director of Education, Dr. Jamani will work collaboratively with members of the committee and harness the expertise of the CTTC community to update and create educational resources and experiences for our community and to make the CTTC website a one-stop shop for high quality educational material.

____________________________________________________________________________________________

A special thanks goes to our outgoing Past-President Dr. Kirk Schultz, outgoing Treasurer Dr. Mahmoud Elsawy, and outgoing Education Director Dr. Wilson Lam, for excellent leadership and steadfast commitment to the CTTC membership and Board of Directors over their respective terms.
 
]]> Wed, 1 Apr 2026 17:17:00 GMT CTTC is seeking nominations for the 2026 Board of Directors https://www.cttcanada.org/news/news.asp?id=713175 https://www.cttcanada.org/news/news.asp?id=713175

The CTTC Board of Directors is seeking nominations for the positions of:

President Elect (2026 - 2028)
Treasurer (2026 - 2029)
Director-at-Large, Education (2026 - 2029)

(Click the links above for more information and to nominate!)

We encourage you to consider nominating yourself or someone you know. Please feel free to reach out to any of the current directors for more information or for a candid conversation about responsibilities.

Please note, to vote or be nominated, you must be a current CTTC member in good standing.

Nominations are due by November 28, 2025

]]> Wed, 29 Oct 2025 17:21:00 GMT CTTC Leadership 2024-2026 https://www.cttcanada.org/news/news.asp?id=669188 https://www.cttcanada.org/news/news.asp?id=669188


CTTC would like to welcome the new CTTC President-Elect for 2024-2026, Dr. Nicole Prokopishyn! It was a very close race, and we thank Dr. Dennis Kim for running in this election.

Dr. Prokopishyn is a clinical assistant professor in the Department of Hematology and the Department of Pathology/Laboratory Medicine at the University of Calgary, and the Chair of Standards for the Foundation of Accreditation of Cellular Therapy (FACT). Dr. Prokopishyn was previously the CTTC Director at Large for Regulatory & Quality, and was instrumental in bringing together the quality committee in Canada to enable learning and collaboration on best practices in Canadian transplant. We are excited to see the future growth of CTTC under the leadership of Dr. Nicole Prokopishyn!


We're also excited to welcome our new President, Dr. Kylie Lepic for 2024-2026 term. Dr. Lepic will take over from Dr. Schultz as the current CTTC President on May 3, during the AGM in Victoria.

Dr. Kylie Lepic is currently the Medical Director of the Cellular Therapy and Transplant Program at the Juravinski Hospital and Cancer Centre in Hamilton and an Associate Professor at McMaster University. She has been an active member of CTTC since completing her Transplant Fellowship at the Fred Hutchinson Cancer Research Centre in Seattle in 2012. She has previously served on the CTTC Board of Directors from 2016 to 2020 as CTTC Director-at-Large Education.

 

A special thanks goes to our outgoing Past-President Dr. Kristjan Paulson for excellent leadership and advice to the Directors over the past two years.

]]> Wed, 3 Apr 2024 18:34:00 GMT Cast your vote now in CTTC's 2024 elections! https://www.cttcanada.org/news/news.asp?id=666114 https://www.cttcanada.org/news/news.asp?id=666114 CTTC 2024 Elections Are Now Open!

CTTC is pleased to announce that the election for CTTC President-Elect (2024-2026), is now open. This is a volunteer Board of Directors position, and two candidates have accepted the nomination. We invite all CTTC members to login and vote for one of the candidates!

                                                                               

                      Dr. Nicole Prokopishyn                                              Dr. Dennis Kim

 

For more information and to vote, CLICK HERE!

 

 

The election closes at noon, March 27, 2024

]]> Wed, 28 Feb 2024 17:10:00 GMT CTTC is seeking nominations for the next President Elect https://www.cttcanada.org/news/news.asp?id=662360 https://www.cttcanada.org/news/news.asp?id=662360

The CTTC executive committee is seeking nominations for the position of:

President Elect (2024 - 2026) (click for job description)

We encourage you to consider nominating yourself or someone you know. Please feel free to reach out to any of the current directors for more information or for a candid conversation about responsibilities.

Please note, to vote or be nominated, you must be a current CTTC member in good standing.

CLICK HERE for more information and to submit your nomination.


Nominations are due by January 24th, 2024

CLICK HERE for more information and to submit your nomination

]]> Fri, 12 Jan 2024 16:14:00 GMT CTTC Welcomes the new Director-At-Large, Research https://www.cttcanada.org/news/news.asp?id=642180 https://www.cttcanada.org/news/news.asp?id=642180 Cell Therapy Transplant Canada (CTTC) is pleased to welcome the organization’s new Director-At-Large, Research: Dr. Jonas Mattsson

Jonas Mattsson is the Director of the Hans Messner Allogeneic Transplant Program at the Princess Margaret Cancer Centre, University Health Network, and a Professor in the Department of Medicine at the University of Toronto, with over 28 years of experience in allogeneic bone marrow transplantation. He also holds the Gloria and Seymour Epstein Chair in Cell Therapy and Transplantation. In addition to overseeing program activities and managing patient care, Dr. Mattsson is involved extensively in clinical and experimental research, primarily in the areas of allogeneic stem cell transplantation and immunotherapy, having published over 250 peer-reviewed articles. Before moving to Toronto, Dr. Mattsson served as a Professor in Cell Therapy at the Karolinska Institute in Stockholm, Sweden, as a Senior Consultant for Clinical Immunology at Karolinska University Hospital, and at the Department of Hematology at Oslo University Hospital in Oslo, Norway. Ongoing research collaboration with the Karolinska Institute continues in Dr. Mattsson’s current role as Visiting Professor. 

The CTTC is recognized internationally with several important publications and prospective trials. Amplification of Canada's footprint in the field of transplantation and cellular therapy, through focused unified direction beyond the aims of individual centres, would strengthen this recognition. In achieving this objective, I envision the CTTC playing two key roles. As a facilitator strengthening and ensuring partnerships across Canadian centres, the CTTC will augment its potential to lead both retrospective and prospective multicentre studies, thereby enhancing greater collaborative publications. Secondly, with Canadian participation in both pharmaceutical and collaborative group trials currently being low, the CTTC would play a key role through active involvement and eventual leadership in clinical trials in transplantation and cellular therapy. Being a focal point of contact for sponsors, this will simplify the process and increase the number of trials. A common factor in these two objectives would be to prioritize younger PIs for CTTC studies, ideally providing an opportunity for members from smaller transplant centres to assume these roles. 

 

Please help us in welcoming Jonas, and in thanking Jean-Sébastien Delisle, who made many excellent contributions as DAL, Research over the past 4 years.

]]> Wed, 7 Jun 2023 16:00:00 GMT CTTC Director-At-Large, Research https://www.cttcanada.org/news/news.asp?id=639045 https://www.cttcanada.org/news/news.asp?id=639045 CTTC is pleased to announce that the election for CTTC Director-at-Large, Research, is now open.  This is a volunteer Board of Directors position, and two candidates have accepted the nomination. We invite all CTTC members to login and vote for one of the candidates:

Dr. Greg Guilcher

Dr. Jonas Mattsson

Voting will close Friday, May 19. For more information or to cast your vote, CLICK HERE.]]> Mon, 1 May 2023 17:10:00 GMT CTTC Welcomes the new Director-At-Large, Quality https://www.cttcanada.org/news/news.asp?id=638151 https://www.cttcanada.org/news/news.asp?id=638151 Cell Therapy Transplant Canada (CTTC) is pleased to welcome the organization’s new Director-At-Large, Quality: Harminder Kaur-Singh

Harminder is an accomplished professional with over 15 years of experience in regulatory compliance and quality improvement in the field of cell therapy. She earned her BSc Specialisation in Cellular and Molecular Biology at Concordia University in Montréal, Québec, and went on to pursue a combined Honours BSc/BA in Forensic Science and Criminology in England.
 
She began her career in pre-clinical research studies before moving into the field of cellular therapy at the Princess Margaret Hospital Orsino Laboratory. She then progressed to Quality manager positions within various transplant teams and quality sectors across Canada, supporting programs in their goals of obtaining Health Canada, Accreditation Canada, FACT, and other certifications.
 
Harminder has been a CPHQ (Certified Professional in Healthcare Quality) and a LEAN Green Belt (SSGB), both since 2015, and has extensive experience leading regulatory compliance and improvement efforts as both an employee and a consultant. Currently, she is the Quality Advisor for the Stem Cell transplant program at CHU Sainte-Justine in Montréal, Québec. In her role, Harminder works with all cell therapy sectors to maintain and develop regulatory compliance and quality improvement efforts.
 
As co-chair of the Quality & Regulatory Committee, Harminder plans on further developing current mandates and projects, increasing outreach and implication internationally. Her goal is to continue the great work done by the prior director, Nicole Prokopishykn, by providing the cell therapy community in Canada access to the appropriate tools, guidance and education opportunities to deal with the challenges associated with development and increasing regulatory complexity.

 

Please help us in welcoming Harminder who will start in June 2023, and in thanking Nicole Prokopishyn, who made many excellent contributions as DAL, Quality over the past 4 years.

]]> Thu, 20 Apr 2023 17:20:00 GMT 2023 Election Nominations are Open https://www.cttcanada.org/news/news.asp?id=631802 https://www.cttcanada.org/news/news.asp?id=631802

 

The CTTC Board of Directors is seeking nominations for the following positions:

Director-At-Large, Research (2023-2026) For a full job description, please click here.

Director-At-Large, Quality (2023-2026) For a full job description, please click here.

 

Click Here for More Information and to Nominate!

]]> Mon, 13 Feb 2023 18:45:00 GMT CTTC President 2022 - 2024 https://www.cttcanada.org/news/news.asp?id=610315 https://www.cttcanada.org/news/news.asp?id=610315 Welcome to the new CTTC President for 2022-2024, Dr. Kirk Schultz!

Congratulations also goes out to Dr. Kylie Lepic, the incoming President-Elect, and special thanks to Past President Dr. Kristjan Paulson for excellent leadership over the past two years.

]]> Mon, 4 Jul 2022 21:46:00 GMT Elections Results: Dr. Kylie Lepic is the new President- Elect https://www.cttcanada.org/news/news.asp?id=607473 https://www.cttcanada.org/news/news.asp?id=607473
Dr. Lepic is the Medical Director of the Cellular Therapy and Transplant Program at the Juravinski Hospital and Cancer Centre in Hamilton and an Associate Professor at McMaster University. She has been an active member of CTTC since 2012, having served as Director-at-Large Education and currently co-chairs the Conference Planning committee. Dr. Lepic will work to continue to make the CTTC a valuable resource and community for healthcare providers and for patients and caregivers.

Please join us in congratulating Dr. Lepic!]]> Thu, 2 Jun 2022 21:35:00 GMT President-Elect https://www.cttcanada.org/news/news.asp?id=604263 https://www.cttcanada.org/news/news.asp?id=604263
The CTTC is pleased to announce that the election for CTTC President-Elect is now open.  This is a volunteer Board of Directors position, and two candidates have accepted the nomination. We invite all CTTC members to login and vote for one of the candidates:



Dr. Kylie Lepic

Dr. Nicole Prokopishyn



Voting Deadline: Wednesday, May 25, 2022

 

CLICK HERE TO VOTE (you must be logged in to cast your vote)

]]> Tue, 3 May 2022 21:23:00 GMT CTTC Executive Committee Seeks Nominations https://www.cttcanada.org/news/news.asp?id=599995 https://www.cttcanada.org/news/news.asp?id=599995

The CTTC executive committee is seeking nominations for the position of:

President Elect (2022 - 2024) (click for job description)

We encourage you to consider nominating yourself or someone you know. Please feel free to reach out to any of the current directors for more information or for a candid conversation about responsibilities. Click the button below to discover more about this position, and to submit a nomination.

Please note, to vote or be nominated, you must be a current CTTC member in good standing.
NOMINATE A CANDIDATE

The deadline for nominations is April 13th, 2022.

 

]]> Wed, 23 Mar 2022 20:29:00 GMT